Picturing Disease

Emily BurkeBiotech Basics, Cancer, Clinical Trials, Diagnostics, Term of the Week, The WEEKLY

USING MEDICAL IMAGING TO INVESTIGATE DISEASE Medical imaging — using various modalities to take a snapshot of the body’s interior structure — has been around since 1895, with the discovery of X-rays by Wilhelm Roentgen. X-rays are a type of electromagnetic radiation (more on that later!) that are able to pass through soft tissues such as skin, fat, and muscle … Read More

A Bone To Pick With Osteoporosis

Emily BurkeBiologics, Clinical Trials, Drug Development, Drug Targets, Mechanism of Action, Monoclonal Antibodies

The Race To Be The Next Big Bone Drug Amgen’s recent positive Phase III results for an antibody drug is putting it neck and neck with Radius Health’s peptide — the latest in a batch of osteoporosis therapies edging their way to the market. The current widely prescribed generic — bisphosphonate — only works to slow the loss of bone, while these newer drugs add to the therapies that aim to rebuild. … Read More

Stomach Stapling Paves A Pathway

Emily BurkeBiologics, Clinical Trials, Diabetes, Drug Development, Drug Targets, Mechanism of Action, The WEEKLY

Identifying Gut Proteins To Tackle Metabolic Disorders Historians of science love to tell about “eureka moments”—simple observations leading to major insight. Greek mathematician Archimedes allegedly exclaimed the original “Eureka!”—meaning “I have found it!”—upon witnessing the volume of water displaced by his body in the bathtub equaled the volume of the body part he had submerged. Medicine’s most famous eureka moment is probably the … Read More

Catching The First Drop Of Cancer

Emily BurkeCancer, Deoxyribonucleic Acid (DNA), Diagnostics, FDA, Monoclonal Antibodies, Ribonucleic Acid (RNA), Term of the Week, The WEEKLY

The Latest In Cancer Diagnostics Hearing the words “it might be cancer” paired with your doctor’s perplexed look is enough to send shockwaves through your body. Getting to the heart of a diagnosis usually requires a surgical biopsy—removal and examination of the suspected tissue for visible signs of cancer. Less invasive diagnostic tests—called liquid biopsies—might just bring more choices to … Read More

Biotech’s Battlefront: Monoclonal Antibodies

Emily BurkeBiologics, Biotech Basics, Cancer, Drug Targets, FDA, Mechanism of Action, Monoclonal Antibodies, Orphan Drugs, The WEEKLY

Since their premier on the scene, monoclonal antibodies (mAb) have demanded top billing on the biotech marquee, creating a cast of therapeutics used to treat diseases like autoimmune disorders and cancer. The first player debuted in 1986 when Janssen-Cilag’s OKT3 gained FDA approval to treat transplant rejection patients. Fast forward to 2013, where half of the top ten best selling … Read More

Saved By Screening

Emily BurkeThe WEEKLY

NEW COMPANION DIAGNOSTIC APPROVAL Colorectal cancer is the third most common cancer found in both men and women in the U.S., and is the second leading cause of cancer deaths. Approximately 1.2 million cases of colorectal cancer are expected to occur globally. Just last week, the FDA approved Qiagen’s Therascreen KRAS companion diagnostic to identify colorectal cancer patients most likely … Read More